Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals
[...]we have found that natural infection with XBB subvariants, including XBB.1.5, does not efficiently induce humoral immunity against the infecting XBB subvariants.1–3 These observations raise the possibility that the XBB.1.5 monovalent vaccine might not be able to efficiently induce humoral immun...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2024-03, Vol.24 (3), p.e147-e148 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e148 |
|---|---|
| container_issue | 3 |
| container_start_page | e147 |
| container_title | The Lancet infectious diseases |
| container_volume | 24 |
| creator | Kosugi, Yusuke Kaku, Yu Hinay, Alfredo A Guo, Ziyi Uriu, Keiya Kihara, Minoru Saito, Fumitake Uwamino, Yoshifumi Kuramochi, Jin Shirakawa, Kotaro Takaori-Kondo, Akifumi Sato, Kei |
| description | [...]we have found that natural infection with XBB subvariants, including XBB.1.5, does not efficiently induce humoral immunity against the infecting XBB subvariants.1–3 These observations raise the possibility that the XBB.1.5 monovalent vaccine might not be able to efficiently induce humoral immunity against emerging SARS-CoV-2 variants, including a variety of XBB subvariants (XBB.1.5, XBB.1.16, XBB.2.3, EG.5.1, and HK.3) as well as BA.2.86. Importantly, in the case of the XBB.1.5 vaccine sera without previous infection, XBB.1.5 vaccine also efficiently induced antiviral activity (2·1-fold to 3·9-fold) against all variants tested with statistical significance (figure A). The induction efficiency of neutralising activity was comparable between the infection-naive cohort (figure A) and the XBB-infected cohort (figure B). [...]although all prevaccination sera from the XBB-infected cohort showed antiviral activity against all variants tested, some individuals vaccinated with XBB.1.5 vaccine without natural infection showed no antiviral activity against XBB.1.5 (n=2), XBB.1.16 (n=1), XBB.2.3 (n=3), EG.5.1 (n=3), HK.3 (n=3), and BA.2.86 (n=2). |
| doi_str_mv | 10.1016/S1473-3099(23)00784-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2929027776</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309923007843</els_id><sourcerecordid>2929027776</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-66fa9768cae2f1515d66442c6c48f32194da8c55e278f83d4b7ae30dcf1b9d33</originalsourceid><addsrcrecordid>eNqFkc1q3DAUhU1paNK0j9Ai6CZdaKI_W9aqTIb0BwKBTijdCVmSWwVbSiXLME-S1608TrvopiC44vLdcy_nVNUbjDYY4eZyjxmnkCIhLgh9jxBvGaTPqrPSZpCxmj8__lfktHqZ0j1CmGPEXlSntCUY10KcVY9bP7nZRTWAn3kMS3XjmL2bDkD9UM6nCey3X_dwF75BAsLodAwepNzNKjrlpwScN1lbA7oD-H51tcGbGozBh1kN1k9gVlo7bwtVXm_15IKHXrnZAuXNMgHXflEoSuUWk9WQXlUnfSn29VM9r-4-Xt_tPsOb209fdtsbqBlDE2yaXgnetFpZ0uMa16ZpGCO60aztKcGCGdXquraEt31LDeu4shQZ3eNOGErPq4tV9iGGX9mmSY4uaTsMytuQkySCCEQ4501B3_2D3occfTlOUkQFx6yt20LVK1VsSinaXj5EN6p4kBjJJTh5DE4uqUhC5TE4uRzy9kk9d6M1f6f-JFWADytgixuzs1Em7awvxrtY3JMmuP-s-A31Z6in</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3039714858</pqid></control><display><type>article</type><title>Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals</title><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Kosugi, Yusuke ; Kaku, Yu ; Hinay, Alfredo A ; Guo, Ziyi ; Uriu, Keiya ; Kihara, Minoru ; Saito, Fumitake ; Uwamino, Yoshifumi ; Kuramochi, Jin ; Shirakawa, Kotaro ; Takaori-Kondo, Akifumi ; Sato, Kei</creator><creatorcontrib>Kosugi, Yusuke ; Kaku, Yu ; Hinay, Alfredo A ; Guo, Ziyi ; Uriu, Keiya ; Kihara, Minoru ; Saito, Fumitake ; Uwamino, Yoshifumi ; Kuramochi, Jin ; Shirakawa, Kotaro ; Takaori-Kondo, Akifumi ; Sato, Kei ; The Genotype to Phenotype Japan (G2P-Japan) Consortium ; Genotype to Phenotype Japan (G2P-Japan) Consortium</creatorcontrib><description>[...]we have found that natural infection with XBB subvariants, including XBB.1.5, does not efficiently induce humoral immunity against the infecting XBB subvariants.1–3 These observations raise the possibility that the XBB.1.5 monovalent vaccine might not be able to efficiently induce humoral immunity against emerging SARS-CoV-2 variants, including a variety of XBB subvariants (XBB.1.5, XBB.1.16, XBB.2.3, EG.5.1, and HK.3) as well as BA.2.86. Importantly, in the case of the XBB.1.5 vaccine sera without previous infection, XBB.1.5 vaccine also efficiently induced antiviral activity (2·1-fold to 3·9-fold) against all variants tested with statistical significance (figure A). The induction efficiency of neutralising activity was comparable between the infection-naive cohort (figure A) and the XBB-infected cohort (figure B). [...]although all prevaccination sera from the XBB-infected cohort showed antiviral activity against all variants tested, some individuals vaccinated with XBB.1.5 vaccine without natural infection showed no antiviral activity against XBB.1.5 (n=2), XBB.1.16 (n=1), XBB.2.3 (n=3), EG.5.1 (n=3), HK.3 (n=3), and BA.2.86 (n=2).</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(23)00784-3</identifier><identifier>PMID: 38211599</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Antiviral activity ; Consortia ; Humoral immunity ; Immunity ; Infections ; R&D ; Research & development ; Severe acute respiratory syndrome coronavirus 2 ; Vaccines</subject><ispartof>The Lancet infectious diseases, 2024-03, Vol.24 (3), p.e147-e148</ispartof><rights>2024 Elsevier Ltd</rights><rights>2024. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-66fa9768cae2f1515d66442c6c48f32194da8c55e278f83d4b7ae30dcf1b9d33</citedby><cites>FETCH-LOGICAL-c440t-66fa9768cae2f1515d66442c6c48f32194da8c55e278f83d4b7ae30dcf1b9d33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/3039714858?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38211599$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kosugi, Yusuke</creatorcontrib><creatorcontrib>Kaku, Yu</creatorcontrib><creatorcontrib>Hinay, Alfredo A</creatorcontrib><creatorcontrib>Guo, Ziyi</creatorcontrib><creatorcontrib>Uriu, Keiya</creatorcontrib><creatorcontrib>Kihara, Minoru</creatorcontrib><creatorcontrib>Saito, Fumitake</creatorcontrib><creatorcontrib>Uwamino, Yoshifumi</creatorcontrib><creatorcontrib>Kuramochi, Jin</creatorcontrib><creatorcontrib>Shirakawa, Kotaro</creatorcontrib><creatorcontrib>Takaori-Kondo, Akifumi</creatorcontrib><creatorcontrib>Sato, Kei</creatorcontrib><creatorcontrib>The Genotype to Phenotype Japan (G2P-Japan) Consortium</creatorcontrib><creatorcontrib>Genotype to Phenotype Japan (G2P-Japan) Consortium</creatorcontrib><title>Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>[...]we have found that natural infection with XBB subvariants, including XBB.1.5, does not efficiently induce humoral immunity against the infecting XBB subvariants.1–3 These observations raise the possibility that the XBB.1.5 monovalent vaccine might not be able to efficiently induce humoral immunity against emerging SARS-CoV-2 variants, including a variety of XBB subvariants (XBB.1.5, XBB.1.16, XBB.2.3, EG.5.1, and HK.3) as well as BA.2.86. Importantly, in the case of the XBB.1.5 vaccine sera without previous infection, XBB.1.5 vaccine also efficiently induced antiviral activity (2·1-fold to 3·9-fold) against all variants tested with statistical significance (figure A). The induction efficiency of neutralising activity was comparable between the infection-naive cohort (figure A) and the XBB-infected cohort (figure B). [...]although all prevaccination sera from the XBB-infected cohort showed antiviral activity against all variants tested, some individuals vaccinated with XBB.1.5 vaccine without natural infection showed no antiviral activity against XBB.1.5 (n=2), XBB.1.16 (n=1), XBB.2.3 (n=3), EG.5.1 (n=3), HK.3 (n=3), and BA.2.86 (n=2).</description><subject>Antiviral activity</subject><subject>Consortia</subject><subject>Humoral immunity</subject><subject>Immunity</subject><subject>Infections</subject><subject>R&D</subject><subject>Research & development</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccines</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkc1q3DAUhU1paNK0j9Ai6CZdaKI_W9aqTIb0BwKBTijdCVmSWwVbSiXLME-S1608TrvopiC44vLdcy_nVNUbjDYY4eZyjxmnkCIhLgh9jxBvGaTPqrPSZpCxmj8__lfktHqZ0j1CmGPEXlSntCUY10KcVY9bP7nZRTWAn3kMS3XjmL2bDkD9UM6nCey3X_dwF75BAsLodAwepNzNKjrlpwScN1lbA7oD-H51tcGbGozBh1kN1k9gVlo7bwtVXm_15IKHXrnZAuXNMgHXflEoSuUWk9WQXlUnfSn29VM9r-4-Xt_tPsOb209fdtsbqBlDE2yaXgnetFpZ0uMa16ZpGCO60aztKcGCGdXquraEt31LDeu4shQZ3eNOGErPq4tV9iGGX9mmSY4uaTsMytuQkySCCEQ4501B3_2D3occfTlOUkQFx6yt20LVK1VsSinaXj5EN6p4kBjJJTh5DE4uqUhC5TE4uRzy9kk9d6M1f6f-JFWADytgixuzs1Em7awvxrtY3JMmuP-s-A31Z6in</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Kosugi, Yusuke</creator><creator>Kaku, Yu</creator><creator>Hinay, Alfredo A</creator><creator>Guo, Ziyi</creator><creator>Uriu, Keiya</creator><creator>Kihara, Minoru</creator><creator>Saito, Fumitake</creator><creator>Uwamino, Yoshifumi</creator><creator>Kuramochi, Jin</creator><creator>Shirakawa, Kotaro</creator><creator>Takaori-Kondo, Akifumi</creator><creator>Sato, Kei</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20240301</creationdate><title>Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals</title><author>Kosugi, Yusuke ; Kaku, Yu ; Hinay, Alfredo A ; Guo, Ziyi ; Uriu, Keiya ; Kihara, Minoru ; Saito, Fumitake ; Uwamino, Yoshifumi ; Kuramochi, Jin ; Shirakawa, Kotaro ; Takaori-Kondo, Akifumi ; Sato, Kei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-66fa9768cae2f1515d66442c6c48f32194da8c55e278f83d4b7ae30dcf1b9d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antiviral activity</topic><topic>Consortia</topic><topic>Humoral immunity</topic><topic>Immunity</topic><topic>Infections</topic><topic>R&D</topic><topic>Research & development</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kosugi, Yusuke</creatorcontrib><creatorcontrib>Kaku, Yu</creatorcontrib><creatorcontrib>Hinay, Alfredo A</creatorcontrib><creatorcontrib>Guo, Ziyi</creatorcontrib><creatorcontrib>Uriu, Keiya</creatorcontrib><creatorcontrib>Kihara, Minoru</creatorcontrib><creatorcontrib>Saito, Fumitake</creatorcontrib><creatorcontrib>Uwamino, Yoshifumi</creatorcontrib><creatorcontrib>Kuramochi, Jin</creatorcontrib><creatorcontrib>Shirakawa, Kotaro</creatorcontrib><creatorcontrib>Takaori-Kondo, Akifumi</creatorcontrib><creatorcontrib>Sato, Kei</creatorcontrib><creatorcontrib>The Genotype to Phenotype Japan (G2P-Japan) Consortium</creatorcontrib><creatorcontrib>Genotype to Phenotype Japan (G2P-Japan) Consortium</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kosugi, Yusuke</au><au>Kaku, Yu</au><au>Hinay, Alfredo A</au><au>Guo, Ziyi</au><au>Uriu, Keiya</au><au>Kihara, Minoru</au><au>Saito, Fumitake</au><au>Uwamino, Yoshifumi</au><au>Kuramochi, Jin</au><au>Shirakawa, Kotaro</au><au>Takaori-Kondo, Akifumi</au><au>Sato, Kei</au><aucorp>The Genotype to Phenotype Japan (G2P-Japan) Consortium</aucorp><aucorp>Genotype to Phenotype Japan (G2P-Japan) Consortium</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>24</volume><issue>3</issue><spage>e147</spage><epage>e148</epage><pages>e147-e148</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><abstract>[...]we have found that natural infection with XBB subvariants, including XBB.1.5, does not efficiently induce humoral immunity against the infecting XBB subvariants.1–3 These observations raise the possibility that the XBB.1.5 monovalent vaccine might not be able to efficiently induce humoral immunity against emerging SARS-CoV-2 variants, including a variety of XBB subvariants (XBB.1.5, XBB.1.16, XBB.2.3, EG.5.1, and HK.3) as well as BA.2.86. Importantly, in the case of the XBB.1.5 vaccine sera without previous infection, XBB.1.5 vaccine also efficiently induced antiviral activity (2·1-fold to 3·9-fold) against all variants tested with statistical significance (figure A). The induction efficiency of neutralising activity was comparable between the infection-naive cohort (figure A) and the XBB-infected cohort (figure B). [...]although all prevaccination sera from the XBB-infected cohort showed antiviral activity against all variants tested, some individuals vaccinated with XBB.1.5 vaccine without natural infection showed no antiviral activity against XBB.1.5 (n=2), XBB.1.16 (n=1), XBB.2.3 (n=3), EG.5.1 (n=3), HK.3 (n=3), and BA.2.86 (n=2).</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>38211599</pmid><doi>10.1016/S1473-3099(23)00784-3</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2024-03, Vol.24 (3), p.e147-e148 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2929027776 |
| source | Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Antiviral activity Consortia Humoral immunity Immunity Infections R&D Research & development Severe acute respiratory syndrome coronavirus 2 Vaccines |
| title | Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T01%3A26%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiviral%20humoral%20immunity%20against%20SARS-CoV-2%20omicron%20subvariants%20induced%20by%20XBB.1.5%20monovalent%20vaccine%20in%20infection-naive%20and%20XBB-infected%20individuals&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Kosugi,%20Yusuke&rft.aucorp=The%20Genotype%20to%20Phenotype%20Japan%20(G2P-Japan)%20Consortium&rft.date=2024-03-01&rft.volume=24&rft.issue=3&rft.spage=e147&rft.epage=e148&rft.pages=e147-e148&rft.issn=1473-3099&rft.eissn=1474-4457&rft_id=info:doi/10.1016/S1473-3099(23)00784-3&rft_dat=%3Cproquest_cross%3E2929027776%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3039714858&rft_id=info:pmid/38211599&rft_els_id=S1473309923007843&rfr_iscdi=true |